Foreign companies are more involved in the formal implementation of a batch of commonly used drugs!

Medical Network News, April 12 For companies, once they win the bid, they will not only obtain the corresponding procurement market, but also restrict the sales of competing products through rules and achieve a new round of market volume.
There will be greater incentives to reduce prices to qualify for the bid.

 

Formally execute

 

On April 9, the Hunan Provincial Public Resource Trading Service Platform issued the "Notice on Doing a Good Job in the Implementation of the Results of the First Batch of Common Drug Purchases in Five Provinces and Cities".

 

According to the notice, in accordance with the spirit of the "Opinions of the CPC Central Committee and the State Council on Deepening the Reform of the Medical Security System", in order to implement the decision and deployment of the Party Central Committee and the State Council on the normalization of centralized drug procurement and use, and to further reduce the burden on the masses of drugs, Hunan Province is actively Participated in the first batch of joint procurement of commonly used drugs in the five provinces and cities of Chongqing, Guizhou, Yunnan, Hunan, and Guangxi Zhuang Autonomous Region (hereinafter referred to as the "five provinces and cities") .
The results of the joint centralized procurement of drugs are now announced.

 

Among them, the scope of drugs is the first batch of commonly used drugs in five provinces and cities to jointly purchase the selected drugs in Hunan.

 

This document dates back to the October 14th "The First Batch of Commonly Used Drugs Joint Procurement Documents (Draft for Comment)" in Chongqing, Guizhou Province, Yunnan Province, Hunan Province, Guangxi Zhuang Autonomous Region, and Guangxi Zhuang Autonomous Region.

 

The documents show that this purchase mainly involves a number of commonly used drugs with large clinical usage, high purchase amount and relatively sufficient competition, including piperacillin, tazobactam, ceftazidime, pantoprazole sodium, levocarnitine, and ligustrazine hydrochloride , Ornidazole Sodium Chloride, Rabeprazole Sodium, etc.
But to the end, only 15 species including piperacillin, tazobactam, ceftazidime, and pantoprazole sodium were confirmed.

 

　　A total of seven drugs were finally selected for the joint collection of Hunan Province, namely Levocarnitine, Ligustrazine Hydrochloride, Somatostatin, Sodium Hyaluronate, Rabeprazona, Bromhexine, and Tiotropium Bromide; a total of Changzhou Lan Ling Pharmaceutical Co.
, Ltd.
, Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co.
, Ltd.
, Pingguang Pharmaceutical Co.
, Ltd.
, and Eisai (China) Pharmaceutical Co.
, Ltd.
were selected.

 

　　Higher participation of foreign companies

 

　　According to the previous documents of the five provinces and cities, the joint centralized procurement varieties are divided into two quality levels, and the quotation requirements shall not be higher than the currently implemented national minimum price.

 

　　The first level of quality: patented drugs, original research drugs, reference preparations, newly registered chemical drugs approved drugs and drugs included in the "China List of Listed Drugs", obtained EU CGMP, US FDA, Japan JGMP certification and exported to Europe and the United States , Domestic drugs in mainstream Japanese market.

 

　　The second quality level: other imported drugs and domestic generic drugs except for the first quality level.

 

　　Judging from the selected drug supply table published by Hunan Province, 8 of the 23 products are the first quality level.
Compared with the result of the national centralized procurement of foreign pharmaceutical companies withdrawing from the market, the five provinces and cities have brought large-scale procurement.
The participation of multinational pharmaceutical companies is relatively high.

 

　　This has a certain relationship with the implementation rules of the five provinces and cities.
Compared with other provinces' bulk procurement plans, the Five Provinces Alliance will monitor non-selected and non-included bulk procurement products, and set up a list of violations to impose certain penalties and penalties.

 

　　Unselected products and products that are not included in volume purchases with the same generic name and route of administration are all included in the monitoring management.
In principle, their purchase volume shall not be higher than the historical purchase volume of the previous year, and shall not exceed the selected drug purchase volume.

 

　　This means that relevant departments centrally monitor the procurement volume of unselected products.
It is difficult for unselected companies to abandon winning bids, focus on expanding the hospital market, and actively promote to gain sales, because the procurement volume of unselected products must not exceed the procurement volume of selected drugs.
Companies can only actively cut prices and strive to win the bid to keep the market.

 

　　This point can also be clearly seen in the procurement documents of Hunan Province: other companies under the generic name of the selected drug are not selected drugs, and the relevant regulations of Hunan Province for drug listing are implemented, and the second quality level listing price is not higher than the first.
Select the price in the quality level to reapply for online listing and include it in the monitoring catalog management of quantity procurement.
Enterprises that fail to declare or fail to declare as required shall be deemed to have given up the qualification for listing of corresponding drugs.

 

　　In addition, medical institutions should unblock the channels for the selected drugs to enter the hospital, and give priority to the use of selected drugs.
In the procurement cycle, for medical institutions that have completed the agreed procurement quantity in advance, the selected company should continue to supply at the selected price until the expiration of the procurement cycle.
Medical institutions can purchase unselected drugs at a reasonable price according to clinical needs for quantities other than planned purchases.
However, in principle, the purchase of selected drugs shall not be less than 70% of the total pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase of all drugs with the same generic name and the same pharmnet.
com.
cn/news/yyzb/" target="_blank">tender formulation at the same time .
pharmnet.
com.
cn/news/yyzb/" target="_blank">

 

　　In order to encourage fair competition, and further play the role of volume procurement to guide the drug market price formation mechanism, if the price of the unselected drug is automatically adjusted to the lowest price of the selected drug of the same quality level and the same generic name and below, after the corresponding selected drug completes the purchase quantity, The unselected drug is not affected by the above restrictions.

 

　　For companies, once they have won the bid, they will not only obtain the corresponding procurement market, but also restrict the sales of competing products through corresponding rules, and have more opportunities to expand the market outside of the bid.
Therefore, they also have greater incentives to reduce prices to qualify for the bid.
More companies are participating in the price war.

　　Medical Network News, April 12 For companies, once they win the bid, they will not only obtain the corresponding procurement market, but also restrict the sales of competing products through rules and achieve a new round of market volume.
There will be greater incentives to reduce prices to qualify for the bid.

 

　　Formally execute

 

　　On April 9, the Hunan Provincial Public Resource Trading Service Platform issued the "Notice on Doing a Good Job in the Implementation of the Results of the First Batch of Common Drug Purchases in Five Provinces and Cities".

 

　　According to the notice, in accordance with the spirit of the "Opinions of the CPC Central Committee and the State Council on Deepening the Reform of the Medical Security System", in order to implement the decision and deployment of the Party Central Committee and the State Council on the normalization of centralized drug procurement and use, and to further reduce the burden on the masses of drugs, Hunan Province is actively Participated in the first batch of joint procurement of commonly used drugs in the five provinces and cities of Chongqing, Guizhou, Yunnan, Hunan, and Guangxi Zhuang Autonomous Region (hereinafter referred to as the "five provinces and cities") .
The results of the joint centralized procurement of drugs are now announced.

 

　　Among them, the scope of drugs is the first batch of commonly used drugs in five provinces and cities to jointly purchase the selected drugs in Hunan.

 

　　This document dates back to the October 14th "The First Batch of Commonly Used Drugs Joint Procurement Documents (Draft for Comment)" in Chongqing, Guizhou Province, Yunnan Province, Hunan Province, Guangxi Zhuang Autonomous Region, and Guangxi Zhuang Autonomous Region.

 

　　The documents show that this purchase mainly involves a number of commonly used drugs with large clinical usage, high purchase amount and relatively sufficient competition, including piperacillin, tazobactam, ceftazidime, pantoprazole sodium, levocarnitine, and ligustrazine hydrochloride , Ornidazole Sodium Chloride, Rabeprazole Sodium, etc.
But to the end, only 15 species including piperacillin, tazobactam, ceftazidime, and pantoprazole sodium were confirmed.

 

　　A total of seven drugs were finally selected for the joint collection of Hunan Province, namely Levocarnitine, Ligustrazine Hydrochloride, Somatostatin, Sodium Hyaluronate, Rabeprazona, Bromhexine, and Tiotropium Bromide; a total of Changzhou Lan Ling Pharmaceutical Co.
, Ltd.
, Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co.
, Ltd.
, Pingguang Pharmaceutical Co.
, Ltd.
, and Eisai (China) Pharmaceutical Co.
, Ltd.
were selected.

 

　　Higher participation of foreign companies

 

　　According to the previous documents of the five provinces and cities, the joint centralized procurement varieties are divided into two quality levels, and the quotation requirements shall not be higher than the currently implemented national minimum price.

 

　　The first level of quality: patented drugs, original research drugs, reference preparations, newly registered chemical drugs approved drugs and drugs included in the "China List of Listed Drugs", obtained EU CGMP, US FDA, Japan JGMP certification and exported to Europe and the United States , Domestic drugs in mainstream Japanese market.

 

　　The second quality level: other imported drugs and domestic generic drugs except for the first quality level.

 

　　Judging from the selected drug supply table published by Hunan Province, 8 of the 23 products are the first quality level.
Compared with the result of the national centralized procurement of foreign pharmaceutical companies withdrawing from the market, the five provinces and cities have brought large-scale procurement.
The participation of multinational pharmaceutical companies is relatively high.

 

　　This has a certain relationship with the implementation rules of the five provinces and cities.
Compared with other provinces' bulk procurement plans, the Five Provinces Alliance will monitor non-selected and non-included bulk procurement products, and set up a list of violations to impose certain penalties and penalties.

 

　　Unselected products and products that are not included in volume purchases with the same generic name and route of administration are all included in the monitoring management.
In principle, their purchase volume shall not be higher than the historical purchase volume of the previous year, and shall not exceed the selected drug purchase volume.

 

　　This means that relevant departments centrally monitor the procurement volume of unselected products.
It is difficult for unselected companies to abandon winning bids, focus on expanding the hospital market, and actively promote to gain sales, because the procurement volume of unselected products must not exceed the procurement volume of selected drugs.
Companies can only actively cut prices and strive to win the bid to keep the market.

 

　　This point can also be clearly seen in the procurement documents of Hunan Province: other companies under the generic name of the selected drug are not selected drugs, and the relevant regulations of Hunan Province for drug listing are implemented, and the second quality level listing price is not higher than the first.
Select the price in the quality level to reapply for online listing and include it in the monitoring catalog management of quantity procurement.
Enterprises that fail to declare or fail to declare as required shall be deemed to have given up the qualification for listing of corresponding drugs.

 

　　In addition, medical institutions should unblock the channels for the selected drugs to enter the hospital, and give priority to the use of selected drugs.
In the procurement cycle, for medical institutions that have completed the agreed procurement quantity in advance, the selected company should continue to supply at the selected price until the expiration of the procurement cycle.
Medical institutions can purchase unselected drugs at a reasonable price according to clinical needs for quantities other than planned purchases.
However, in principle, the purchase of selected drugs shall not be less than 70% of the total pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase of all drugs with the same generic name and the same pharmnet.
com.
cn/news/yyzb/" target="_blank">tender formulation at the same time .
pharmnet.
com.
cn/news/yyzb/" target="_blank">

 

　　In order to encourage fair competition, and further play the role of volume procurement to guide the drug market price formation mechanism, if the price of the unselected drug is automatically adjusted to the lowest price of the selected drug of the same quality level and the same generic name and below, after the corresponding selected drug completes the purchase quantity, The unselected drug is not affected by the above restrictions.

 

　　For companies, once they have won the bid, they will not only obtain the corresponding procurement market, but also restrict the sales of competing products through corresponding rules, and have more opportunities to expand the market outside of the bid.
Therefore, they also have greater incentives to reduce prices to qualify for the bid.
More companies are participating in the price war.